Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458275 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL13430643 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL20491430 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL14185446 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL2961995 | 1.00 | — | — | |
| SCHEMBL7113798 | 1.00 | CHRM5 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL10793 | 1.00 | — | — | |
| SCHEMBL1345379 | 0.97 | — | — | |
| SCHEMBL5346771 | 0.97 | — | — | |
| SCHEMBL7846 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124617-B2 | Materials coated with calixarenes | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2021-09-21 | — | — | US | disclosed |
| EP-2836539-B1 | MATERIALS COATED WITH CALIXARENES | UNIV LIBRE DE BRUXELLES ULB (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-20190233358-A1 | MATERIALS COATED WITH CALIXARENES | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2019-08-01 | — | — | US | disclosed |
| US-10329232-B2 | Materials coated with calixarenes | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2019-06-25 | — | — | US | disclosed |
| CN-104487496-B | The material coated through calixarenes | 布鲁塞尔私立大学 | 2018-09-18 | — | — | CN | disclosed |
| EP-2522669-B1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-28 | — | — | EP | disclosed |
| US-20150064455-A1 | MATERIALS COATED WITH CALIXARENES | UNIVERSITÉ PARIS CITÉ (FR) | 2015-03-05 | — | — | US | disclosed |
| EP-2836539-A1 | MATERIALS COATED WITH CALIXARENES | Université Libre de Bruxelles (ULB) (BE) | 2015-02-18 | — | — | EP | disclosed |
| EP-2703404-A1 | Buprenorphine analogs | Purdue Pharma L.P. (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2326651-B1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA LP (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998007308-A2 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| EP-0000950-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF AND THEIR SYNTHESIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | disclosed |
| US-4317830-A | ANTISHOCK AGENTS, ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000950-A1 | Imidazole derivatives and salts thereof and their synthesis | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124617-B2 | Materials coated with calixarenes | CALD1, CALU, CALR | CHRM5 1530/4885CYP1A2 1780/4885ADRA2C 1667/4885 |
| US-10329232-B2 | Materials coated with calixarenes | CALU, CALD1, CALR | CHRM5 2623/4885CYP1A2 2082/4885ADRA2C 1830/4885 |
| US-20150064455-A1 | MATERIALS COATED WITH CALIXARENES | CALD1, CALU, CALR | CHRM5 1530/4885CYP1A2 1780/4885ADRA2C 1667/4885 |
| US-20190233358-A1 | MATERIALS COATED WITH CALIXARENES | CALD1, CALU, CALR | CHRM5 1530/4885CYP1A2 1780/4885ADRA2C 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.